Subtopic Deep Dive
Fc Receptor Interactions Antibodies
Research Guide
What is Fc Receptor Interactions Antibodies?
Fc receptor interactions with antibodies refer to the binding of IgG-Fc regions to Fcγ receptors that regulate antibody-dependent cellular cytotoxicity (ADCC), phagocytosis (ADCP), and inflammatory responses.
This subtopic examines how activating and inhibitory FcγRs control immune effector functions of monoclonal antibodies. Key studies highlight subclass-specific affinities, such as IgG1's strong binding to FcγRIIIa for ADCC (Nimmerjahn and Ravetch, 2007; 2792 citations). Over 10,000 papers explore glycoengineering to modulate these interactions.
Why It Matters
Fc engineering optimizes antibodies for cancer immunotherapy by enhancing ADCC while minimizing inflammation, as shown in rituximab trials for multiple sclerosis where B-cell depletion reduced relapses (Hauser et al., 2008; 2359 citations). In rheumatoid arthritis, TNF receptor:Fc fusions like etanercept improved outcomes with methotrexate (Weinblatt et al., 1999; 2090 citations). These interactions determine therapeutic efficacy and safety in over 100 approved biologics.
Key Research Challenges
Subclass Binding Variability
IgG subclasses differ in FcγR affinities, complicating predictions for polyclonal mixtures (Vidarrson et al., 2014; 2514 citations). Engineering must balance activation and inhibition. Clinical translation varies across diseases.
Glycosylation Impact on Effectors
Fc glycosylation alters FcγR binding and ADCC potency (Reily et al., 2019; 2008 citations). Removing fucose enhances affinity but risks immunogenicity. Standardized glycoengineering remains inconsistent.
Inhibitory Receptor Dominance
FcγRIIb inhibits cytotoxicity, limiting tumor targeting as demonstrated in vivo (Clynes et al., 2000; 2706 citations). Silencing mutations are hard to optimize. Balancing pro- and anti-inflammatory signals challenges therapy design.
Essential Papers
Fcγ receptors as regulators of immune responses
Falk Nimmerjahn, Jeffrey V. Ravetch · 2007 · Nature reviews. Immunology · 2.8K citations
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Raphael Clynes, Terri L. Towers, Leonard G. Presta et al. · 2000 · Nature Medicine · 2.7K citations
IgG Subclasses and Allotypes: From Structure to Effector Functions
Gestur Vidarsson, Gillian Dekkers, Theo Rispens · 2014 · Frontiers in Immunology · 2.5K citations
Of the five immunoglobulin isotypes, immunoglobulin G (IgG) is most abundant in human serum. The four subclasses, IgG1, IgG2, IgG3, and IgG4, which are highly conserved, differ in their constant re...
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
Stephen L. Hauser, Emmanuelle Waubant, Douglas L. Arnold et al. · 2008 · New England Journal of Medicine · 2.4K citations
A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks. This trial was not designed to assess long-term safety or to detect uncommon adverse events. The ...
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian, Shreeram Akilesh · 2007 · Nature reviews. Immunology · 2.2K citations
CTLA-4 can function as a negative regulator of T cell activation
Theresa L. Walunas, Deborah J. Lenschow, Christina Y. Bakker et al. · 1994 · Immunity · 2.2K citations
Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics
Sumedha D. Jayasena · 1999 · Clinical Chemistry · 2.1K citations
Abstract Antibodies, the most popular class of molecules providing molecular recognition needs for a wide range of applications, have been around for more than three decades. As a result, antibodie...
Reading Guide
Foundational Papers
Start with Nimmerjahn and Ravetch (2007) for FcγR regulation overview (2792 citations), then Clynes et al. (2000) for inhibitory mechanisms in tumors (2706 citations), followed by Vidarrson et al. (2014) on subclass structures (2514 citations).
Recent Advances
Lu et al. (2020) details therapeutic antibody developments (2046 citations); Reily et al. (2019) covers glycosylation effects (2008 citations).
Core Methods
FcγR binding assays (SPR, ELISA); glyco-profiling (MS); effector function tests (ADCC, ADCP); silencing mutations (N297A, LALA).
How PapersFlow Helps You Research Fc Receptor Interactions Antibodies
Discover & Search
Research Agent uses citationGraph on Nimmerjahn and Ravetch (2007) to map 2792-cited works linking FcγRs to ADCC regulation, then findSimilarPapers reveals glycoengineering extensions like Vidarrson et al. (2014). exaSearch queries 'FcγRIIIa IgG1 glycoengineering' for 500+ recent preclinical studies.
Analyze & Verify
Analysis Agent applies readPaperContent to Clynes et al. (2000) for inhibitory Fc effects data, then runPythonAnalysis plots binding affinities with pandas/matplotlib from extracted tables. verifyResponse with CoVe and GRADE scores evidence on rituximab ADCC claims (Hauser et al., 2008), flagging contradictions in subclass data.
Synthesize & Write
Synthesis Agent detects gaps in Fc silencing for inflammation control via contradiction flagging across Roopenian and Akilesh (2007) and Weinblatt et al. (1999). Writing Agent uses latexEditText to draft effector function reviews, latexSyncCitations for 20-paper bibliographies, and latexCompile for publication-ready figures; exportMermaid visualizes FcγR signaling pathways.
Use Cases
"Analyze FcγR binding affinities from Vidarrson 2014 subclass data"
Analysis Agent → readPaperContent (extracts CH2 domain tables) → runPythonAnalysis (NumPy/pandas computes IgG1-FcγRIIIa KD values, matplotlib affinity heatmaps) → researcher gets quantitative binding models and statistical p-values.
"Draft LaTeX review on Fc engineering for ADCC enhancement"
Synthesis Agent → gap detection (flags glycoengineering voids post-Nimmerjahn 2007) → Writing Agent → latexEditText (structures sections) → latexSyncCitations (integrates 15 refs) → latexCompile → researcher gets compiled PDF with effector diagrams.
"Find code for Fc receptor interaction simulations"
Research Agent → searchPapers 'FcγR simulation' → paperExtractUrls → paperFindGithubRepo → githubRepoInspect (inspects docking scripts) → researcher gets runnable Python sims for IgG-FcγRIIIa binding energies.
Automated Workflows
Deep Research workflow scans 50+ FcγR papers via searchPapers → citationGraph → structured report on ADCC modulators with GRADE scores. DeepScan's 7-step chain verifies Clynes et al. (2000) claims with CoVe checkpoints and runPythonAnalysis on cytotoxicity data. Theorizer generates hypotheses on FcRn-FcγR crosstalk from Roopenian (2007) and Nimmerjahn datasets.
Frequently Asked Questions
What defines Fc receptor interactions with antibodies?
IgG-Fc binds FcγRs to trigger ADCC/ADCP or inhibition via FcγRIIb (Nimmerjahn and Ravetch, 2007).
What methods study these interactions?
Surface plasmon resonance measures affinities; glycoengineering uses afucosylation for ADCC boost (Vidarrson et al., 2014).
What are key papers?
Nimmerjahn and Ravetch (2007; 2792 cites) on regulation; Clynes et al. (2000; 2706 cites) on inhibitory roles.
What open problems exist?
Predicting polyclonal FcγR effects in vivo; optimizing dual FcγR/FcRn engineering without immunogenicity.
Research Monoclonal and Polyclonal Antibodies Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Fc Receptor Interactions Antibodies with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers